PDB Short entry for 2WIH HEADER TRANSFERASE 13-MAY-09 2WIH TITLE STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: P33 PROTEIN KINASE; COMPND 5 EC: 2.7.1.37; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: CYCLIN-A2; COMPND 9 CHAIN: B, D; COMPND 10 FRAGMENT: C-TERMINAL PORTION, RESIDUES 173-432; COMPND 11 SYNONYM: CYCLIN A, CYCLIN A2; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: TRICHOPLUSIA NI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7111; SOURCE 7 EXPRESSION_SYSTEM_CELL_LINE: HIGH FIVE; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 15 EXPRESSION_SYSTEM_PLASMID: PGEX6P KEYWDS CELL CYCLE, ATP-BINDING, TRANSFERASE, POLYMORPHISM, PHOSPHORYLATION, KEYWDS 2 NUCLEOTIDE-BINDING, CELL DIVISION, SERINE/THREONINE-PROTEIN 2 KEYWDS 3 KINASE, PHOSPHOPROTEIN, SERINE/THREONINE-PROTEIN KINASE, MITOSIS EXPDTA X-RAY DIFFRACTION AUTHOR M.G.BRASCA,N.AMBOLDI,D.BALLINARI,A.D.CAMERON,E.CASALE,G.CERVI, AUTHOR 2 M.COLOMBO,F.COLOTTA,V.CROCI,R.DALESSIO,F.FIORENTINI,A.ISACCHI, AUTHOR 3 C.MERCURIO,W.MORETTI,A.PANZERI,W.PASTORI,P.PEVARELLO,F.QUARTIERI, AUTHOR 4 F.ROLETTO,G.TRAQUANDI,P.VIANELLO,A.VULPETTI,M.CIOMEI REVDAT 3 03-APR-19 2WIH 1 SOURCE REVDAT 2 20-APR-11 2WIH 1 KEYWDS JRNL REMARK DBREF REVDAT 2 2 1 SEQADV FORMUL REVDAT 1 28-JUL-09 2WIH 0 JRNL AUTH M.G.BRASCA,N.AMBOLDI,D.BALLINARI,A.D.CAMERON,E.CASALE, JRNL AUTH 2 G.CERVI,M.COLOMBO,F.COLOTTA,V.CROCI,R.DALESSIO,F.FIORENTINI, JRNL AUTH 3 A.ISACCHI,C.MERCURIO,W.MORETTI,A.PANZERI,W.PASTORI, JRNL AUTH 4 P.PEVARELLO,F.QUARTIERI,F.ROLETTO,G.TRAQUANDI,P.VIANELLO, JRNL AUTH 5 A.VULPETTI,M.CIOMEI JRNL TITL IDENTIFICATION OF JRNL TITL 2 N,1,4,4-TETRAMETHYL-8-{[4-(4-METHYLPIPERAZIN-1-YL) JRNL TITL 3 PHENYL]AMINO}-4,5-DIHYDRO-1H-PYRAZOLO[4, JRNL TITL 4 3-H]QUINAZOLINE-3-CARBOXAMIDE (PHA-848125), A POTENT, ORALLY JRNL TITL 5 AVAILABLE CYCLIN DEPENDENT KINASE INHIBITOR. JRNL REF J.MED.CHEM. V. 52 5152 2009 JRNL REFN ISSN 0022-2623 JRNL PMID 19603809 JRNL DOI 10.1021/JM9006559 REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.96 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 4212802.710 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.6 REMARK 3 NUMBER OF REFLECTIONS : 72889 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.215 REMARK 3 R VALUE (WORKING SET) : 0.213 REMARK 3 FREE R VALUE : 0.250 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 3685 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.004 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2350 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.2330 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.264 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 3685 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0040 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 72889 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.66 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.90 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 11358 REMARK 3 BIN R VALUE (WORKING SET) : 0.2930 REMARK 3 BIN FREE R VALUE : 0.3350 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.10 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 611 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.014 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 8976 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 73 REMARK 3 SOLVENT ATOMS : 214 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 45.60 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 48.50 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 5.95000 REMARK 3 B22 (A**2) : 5.95000 REMARK 3 B33 (A**2) : -11.91000 REMARK 3 B12 (A**2) : 7.54000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.32 REMARK 3 ESD FROM SIGMAA (A) : 0.32 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.38 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.38 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.006 REMARK 3 BOND ANGLES (DEGREES) : 0.900 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 21.00 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.690 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.470 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.500 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.190 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.350 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.32 REMARK 3 BSOL : 24.46 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : 125.PAR REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : 125.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THERE IS A FEATURE IN THE ELECTRON REMARK 3 DENSITY MAP ATTACHED TO ASP 28 OF BOTH CDK2 MOLECULES THAT COULD REMARK 3 NOT BE ASSIGNED TO ANY MOLECULE IN THE CRYSTALLISATION MIXTURE. REMARK 3 THIS HAS BEEN MODELLED BY WATER MOLECULES. REMARK 4 REMARK 4 2WIH COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 13-MAY-09. REMARK 100 THE DEPOSITION ID IS D_1290039796. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 28-APR-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-4 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 72932 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.500 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.7 REMARK 200 DATA REDUNDANCY : 7.000 REMARK 200 R MERGE (I) : 0.09000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 16.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.60 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 0.00 REMARK 200 R MERGE FOR SHELL (I) : 0.57000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NONE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 64.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 4.00 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% AMMONIUM SULPHATE, 1M KCL, 40MM REMARK 280 HEPES PH 7 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 62 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 -X,-Y,Z REMARK 290 5555 Y,-X+Y,Z+2/3 REMARK 290 6555 X-Y,X,Z+1/3 REMARK 290 7555 Y,X,-Z+2/3 REMARK 290 8555 X-Y,-Y,-Z REMARK 290 9555 -X,-X+Y,-Z+1/3 REMARK 290 10555 -Y,-X,-Z+2/3 REMARK 290 11555 -X+Y,Y,-Z REMARK 290 12555 X,X-Y,-Z+1/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 142.37333 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 71.18667 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 142.37333 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 71.18667 REMARK 290 SMTRY1 7 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 7 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 142.37333 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 9 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 9 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 9 0.000000 0.000000 -1.000000 71.18667 REMARK 290 SMTRY1 10 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 10 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 10 0.000000 0.000000 -1.000000 142.37333 REMARK 290 SMTRY1 11 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 11 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 11 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 12 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 12 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 12 0.000000 0.000000 -1.000000 71.18667 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2920 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23500 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -10.5 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3230 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23010 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -22.3 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -4 REMARK 465 GLU A 299 REMARK 465 ARG A 300 REMARK 465 PRO A 301 REMARK 465 HIS A 302 REMARK 465 ARG A 303 REMARK 465 ASP A 304 REMARK 465 GLY B 168 REMARK 465 PRO B 169 REMARK 465 LEU B 170 REMARK 465 GLY B 171 REMARK 465 SER B 172 REMARK 465 ASN B 173 REMARK 465 GLU B 174 REMARK 465 VAL B 175 REMARK 465 GLY C -4 REMARK 465 PRO C -3 REMARK 465 LEU C -2 REMARK 465 VAL C -1 REMARK 465 GLU C 299 REMARK 465 ARG C 300 REMARK 465 PRO C 301 REMARK 465 HIS C 302 REMARK 465 ARG C 303 REMARK 465 ASP C 304 REMARK 465 GLY D 168 REMARK 465 PRO D 169 REMARK 465 LEU D 170 REMARK 465 GLY D 171 REMARK 465 SER D 172 REMARK 465 ASN D 173 REMARK 465 GLU D 174 REMARK 465 VAL D 175 REMARK 465 GLN D 323 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 VAL A 7 -61.80 -96.84 REMARK 500 GLU A 40 -30.91 -135.86 REMARK 500 ARG A 126 -0.51 79.63 REMARK 500 ASP A 145 78.82 62.06 REMARK 500 CYS B 193 32.36 -81.39 REMARK 500 PHE B 304 12.91 59.65 REMARK 500 TRP B 372 109.44 -34.17 REMARK 500 GLU C 42 -50.43 -132.77 REMARK 500 HIS C 121 31.83 -98.35 REMARK 500 ARG C 126 -5.97 76.18 REMARK 500 ASP C 145 87.79 64.60 REMARK 500 GLU C 162 152.64 -45.20 REMARK 500 VAL C 163 -70.30 -125.83 REMARK 500 ARG C 297 92.10 -69.23 REMARK 500 CYS D 193 37.64 -85.83 REMARK 500 PHE D 304 14.70 57.62 REMARK 500 LEU D 320 10.15 -68.61 REMARK 500 TRP D 372 106.27 -32.22 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 D 1433 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE P48 C 1299 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE P48 A 1299 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 2VTH RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2-ONE REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2UUE RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 2VTA RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 2WHA RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2VTT RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 2VTQ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR REMARK 900 OLOMOUCINE. REMARK 900 RELATED ID: 2W05 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, REMARK 900 COMPOUND 5B REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 2A0C RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9- REMARK 900 TRISUBSTITUTED PURINE CYCLIN -DEPENDENT KINASE INHIBITOR REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 2UZE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2VTM RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2V0D RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D REMARK 900 MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 2WHB RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2W06 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, REMARK 900 COMPOUND 5C REMARK 900 RELATED ID: 2VTN RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1YKR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR REMARK 900 RELATED ID: 2W17 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2UZD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 2J9M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC REMARK 900 AMINOPYRIMIDINE REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 2VTI RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 2VTS RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2UZN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 2UZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A REMARK 900 PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2G9X RELATED DB: PDB REMARK 900 STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/ CYCLIN A INCOMPLEX WITH REMARK 900 THE INHIBITOR NU6271 REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 2IW9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2- REMARK 900 YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 2VTP RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2A4L RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 2W1H RELATED DB: PDB REMARK 900 FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4- YL UREA (AT9283), A REMARK 900 MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY REMARK 900 RELATED ID: 2VU3 RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE REMARK 900 DIN-101312 REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 2JGZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 5-BROMO-INDIRUBINE REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 2VTL RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 2WFY RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2UZB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2VTJ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 REMARK 900 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2WEV RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 2V22 RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 2VV9 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 2VTO RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2UZO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 900 RELATED ID: 2CLX RELATED DB: PDB REMARK 900 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, REMARK 900 CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR REMARK 900 EFFECTS REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE REMARK 900 PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 2VTR RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR DBREF 2WIH A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2WIH B 173 432 UNP P20248 CCNA2_HUMAN 173 432 DBREF 2WIH C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2WIH D 173 432 UNP P20248 CCNA2_HUMAN 173 432 SEQADV 2WIH GLY A -4 UNP P24941 EXPRESSION TAG SEQADV 2WIH PRO A -3 UNP P24941 EXPRESSION TAG SEQADV 2WIH LEU A -2 UNP P24941 EXPRESSION TAG SEQADV 2WIH VAL A -1 UNP P24941 EXPRESSION TAG SEQADV 2WIH ASP A 0 UNP P24941 EXPRESSION TAG SEQADV 2WIH GLU A 299 UNP P24941 EXPRESSION TAG SEQADV 2WIH ARG A 300 UNP P24941 EXPRESSION TAG SEQADV 2WIH PRO A 301 UNP P24941 EXPRESSION TAG SEQADV 2WIH HIS A 302 UNP P24941 EXPRESSION TAG SEQADV 2WIH ARG A 303 UNP P24941 EXPRESSION TAG SEQADV 2WIH ASP A 304 UNP P24941 EXPRESSION TAG SEQADV 2WIH GLY B 168 UNP P20248 EXPRESSION TAG SEQADV 2WIH PRO B 169 UNP P20248 EXPRESSION TAG SEQADV 2WIH LEU B 170 UNP P20248 EXPRESSION TAG SEQADV 2WIH GLY B 171 UNP P20248 EXPRESSION TAG SEQADV 2WIH SER B 172 UNP P20248 EXPRESSION TAG SEQADV 2WIH GLY C -4 UNP P24941 EXPRESSION TAG SEQADV 2WIH PRO C -3 UNP P24941 EXPRESSION TAG SEQADV 2WIH LEU C -2 UNP P24941 EXPRESSION TAG SEQADV 2WIH VAL C -1 UNP P24941 EXPRESSION TAG SEQADV 2WIH ASP C 0 UNP P24941 EXPRESSION TAG SEQADV 2WIH GLU C 299 UNP P24941 EXPRESSION TAG SEQADV 2WIH ARG C 300 UNP P24941 EXPRESSION TAG SEQADV 2WIH PRO C 301 UNP P24941 EXPRESSION TAG SEQADV 2WIH HIS C 302 UNP P24941 EXPRESSION TAG SEQADV 2WIH ARG C 303 UNP P24941 EXPRESSION TAG SEQADV 2WIH ASP C 304 UNP P24941 EXPRESSION TAG SEQADV 2WIH GLY D 168 UNP P20248 EXPRESSION TAG SEQADV 2WIH PRO D 169 UNP P20248 EXPRESSION TAG SEQADV 2WIH LEU D 170 UNP P20248 EXPRESSION TAG SEQADV 2WIH GLY D 171 UNP P20248 EXPRESSION TAG SEQADV 2WIH SER D 172 UNP P20248 EXPRESSION TAG SEQRES 1 A 309 GLY PRO LEU VAL ASP MET GLU ASN PHE GLN LYS VAL GLU SEQRES 2 A 309 LYS ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA SEQRES 3 A 309 ARG ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS SEQRES 4 A 309 ILE ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR SEQRES 5 A 309 ALA ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS SEQRES 6 A 309 PRO ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU SEQRES 7 A 309 ASN LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP SEQRES 8 A 309 LEU LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE SEQRES 9 A 309 PRO LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU SEQRES 10 A 309 GLN GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS SEQRES 11 A 309 ARG ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU SEQRES 12 A 309 GLY ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA SEQRES 13 A 309 PHE GLY VAL PRO VAL ARG THR TYR THR HIS GLU VAL VAL SEQRES 14 A 309 THR LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS SEQRES 15 A 309 LYS TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY SEQRES 16 A 309 CYS ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE SEQRES 17 A 309 PRO GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE SEQRES 18 A 309 ARG THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY SEQRES 19 A 309 VAL THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS SEQRES 20 A 309 TRP ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU SEQRES 21 A 309 ASP GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS SEQRES 22 A 309 TYR ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU SEQRES 23 A 309 ALA HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO SEQRES 24 A 309 HIS LEU ARG LEU GLU ARG PRO HIS ARG ASP SEQRES 1 B 265 GLY PRO LEU GLY SER ASN GLU VAL PRO ASP TYR HIS GLU SEQRES 2 B 265 ASP ILE HIS THR TYR LEU ARG GLU MET GLU VAL LYS CYS SEQRES 3 B 265 LYS PRO LYS VAL GLY TYR MET LYS LYS GLN PRO ASP ILE SEQRES 4 B 265 THR ASN SER MET ARG ALA ILE LEU VAL ASP TRP LEU VAL SEQRES 5 B 265 GLU VAL GLY GLU GLU TYR LYS LEU GLN ASN GLU THR LEU SEQRES 6 B 265 HIS LEU ALA VAL ASN TYR ILE ASP ARG PHE LEU SER SER SEQRES 7 B 265 MET SER VAL LEU ARG GLY LYS LEU GLN LEU VAL GLY THR SEQRES 8 B 265 ALA ALA MET LEU LEU ALA SER LYS PHE GLU GLU ILE TYR SEQRES 9 B 265 PRO PRO GLU VAL ALA GLU PHE VAL TYR ILE THR ASP ASP SEQRES 10 B 265 THR TYR THR LYS LYS GLN VAL LEU ARG MET GLU HIS LEU SEQRES 11 B 265 VAL LEU LYS VAL LEU THR PHE ASP LEU ALA ALA PRO THR SEQRES 12 B 265 VAL ASN GLN PHE LEU THR GLN TYR PHE LEU HIS GLN GLN SEQRES 13 B 265 PRO ALA ASN CYS LYS VAL GLU SER LEU ALA MET PHE LEU SEQRES 14 B 265 GLY GLU LEU SER LEU ILE ASP ALA ASP PRO TYR LEU LYS SEQRES 15 B 265 TYR LEU PRO SER VAL ILE ALA GLY ALA ALA PHE HIS LEU SEQRES 16 B 265 ALA LEU TYR THR VAL THR GLY GLN SER TRP PRO GLU SER SEQRES 17 B 265 LEU ILE ARG LYS THR GLY TYR THR LEU GLU SER LEU LYS SEQRES 18 B 265 PRO CYS LEU MET ASP LEU HIS GLN THR TYR LEU LYS ALA SEQRES 19 B 265 PRO GLN HIS ALA GLN GLN SER ILE ARG GLU LYS TYR LYS SEQRES 20 B 265 ASN SER LYS TYR HIS GLY VAL SER LEU LEU ASN PRO PRO SEQRES 21 B 265 GLU THR LEU ASN LEU SEQRES 1 C 309 GLY PRO LEU VAL ASP MET GLU ASN PHE GLN LYS VAL GLU SEQRES 2 C 309 LYS ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA SEQRES 3 C 309 ARG ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS SEQRES 4 C 309 ILE ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR SEQRES 5 C 309 ALA ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS SEQRES 6 C 309 PRO ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU SEQRES 7 C 309 ASN LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP SEQRES 8 C 309 LEU LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE SEQRES 9 C 309 PRO LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU SEQRES 10 C 309 GLN GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS SEQRES 11 C 309 ARG ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU SEQRES 12 C 309 GLY ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA SEQRES 13 C 309 PHE GLY VAL PRO VAL ARG THR TYR THR HIS GLU VAL VAL SEQRES 14 C 309 THR LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS SEQRES 15 C 309 LYS TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY SEQRES 16 C 309 CYS ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE SEQRES 17 C 309 PRO GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE SEQRES 18 C 309 ARG THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY SEQRES 19 C 309 VAL THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS SEQRES 20 C 309 TRP ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU SEQRES 21 C 309 ASP GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS SEQRES 22 C 309 TYR ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU SEQRES 23 C 309 ALA HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO SEQRES 24 C 309 HIS LEU ARG LEU GLU ARG PRO HIS ARG ASP SEQRES 1 D 265 GLY PRO LEU GLY SER ASN GLU VAL PRO ASP TYR HIS GLU SEQRES 2 D 265 ASP ILE HIS THR TYR LEU ARG GLU MET GLU VAL LYS CYS SEQRES 3 D 265 LYS PRO LYS VAL GLY TYR MET LYS LYS GLN PRO ASP ILE SEQRES 4 D 265 THR ASN SER MET ARG ALA ILE LEU VAL ASP TRP LEU VAL SEQRES 5 D 265 GLU VAL GLY GLU GLU TYR LYS LEU GLN ASN GLU THR LEU SEQRES 6 D 265 HIS LEU ALA VAL ASN TYR ILE ASP ARG PHE LEU SER SER SEQRES 7 D 265 MET SER VAL LEU ARG GLY LYS LEU GLN LEU VAL GLY THR SEQRES 8 D 265 ALA ALA MET LEU LEU ALA SER LYS PHE GLU GLU ILE TYR SEQRES 9 D 265 PRO PRO GLU VAL ALA GLU PHE VAL TYR ILE THR ASP ASP SEQRES 10 D 265 THR TYR THR LYS LYS GLN VAL LEU ARG MET GLU HIS LEU SEQRES 11 D 265 VAL LEU LYS VAL LEU THR PHE ASP LEU ALA ALA PRO THR SEQRES 12 D 265 VAL ASN GLN PHE LEU THR GLN TYR PHE LEU HIS GLN GLN SEQRES 13 D 265 PRO ALA ASN CYS LYS VAL GLU SER LEU ALA MET PHE LEU SEQRES 14 D 265 GLY GLU LEU SER LEU ILE ASP ALA ASP PRO TYR LEU LYS SEQRES 15 D 265 TYR LEU PRO SER VAL ILE ALA GLY ALA ALA PHE HIS LEU SEQRES 16 D 265 ALA LEU TYR THR VAL THR GLY GLN SER TRP PRO GLU SER SEQRES 17 D 265 LEU ILE ARG LYS THR GLY TYR THR LEU GLU SER LEU LYS SEQRES 18 D 265 PRO CYS LEU MET ASP LEU HIS GLN THR TYR LEU LYS ALA SEQRES 19 D 265 PRO GLN HIS ALA GLN GLN SER ILE ARG GLU LYS TYR LYS SEQRES 20 D 265 ASN SER LYS TYR HIS GLY VAL SER LEU LEU ASN PRO PRO SEQRES 21 D 265 GLU THR LEU ASN LEU HET P48 A1299 34 HET P48 C1299 34 HET SO4 D1433 5 HETNAM P48 N,1,4,4-TETRAMETHYL-8-{[4-(4-METHYLPIPERAZIN-1-YL) HETNAM 2 P48 PHENYL]AMINO}-4,5-DIHYDRO-1H-PYRAZOLO[4,3- HETNAM 3 P48 H]QUINAZOLINE-3-CARBOXAMIDE HETNAM SO4 SULFATE ION FORMUL 5 P48 2(C25 H32 N8 O) FORMUL 7 SO4 O4 S 2- FORMUL 8 HOH *214(H2 O) HELIX 1 1 PRO A -3 ASN A 3 1 7 HELIX 2 2 PRO A 45 LYS A 56 1 12 HELIX 3 3 LEU A 87 SER A 94 1 8 HELIX 4 4 PRO A 100 HIS A 121 1 22 HELIX 5 5 LYS A 129 GLN A 131 5 3 HELIX 6 6 THR A 165 ARG A 169 5 5 HELIX 7 7 ALA A 170 LEU A 175 1 6 HELIX 8 8 THR A 182 ARG A 199 1 18 HELIX 9 9 SER A 207 GLY A 220 1 14 HELIX 10 10 GLY A 229 MET A 233 5 5 HELIX 11 11 ASP A 256 LEU A 267 1 12 HELIX 12 12 SER A 276 LEU A 281 1 6 HELIX 13 13 ALA A 282 GLN A 287 5 6 HELIX 14 14 TYR B 178 CYS B 193 1 16 HELIX 15 15 GLY B 198 GLN B 203 5 6 HELIX 16 16 THR B 207 TYR B 225 1 19 HELIX 17 17 GLN B 228 LEU B 243 1 16 HELIX 18 18 LEU B 249 GLU B 269 1 21 HELIX 19 19 GLU B 274 ILE B 281 1 8 HELIX 20 20 THR B 287 THR B 303 1 17 HELIX 21 21 THR B 310 LEU B 320 1 11 HELIX 22 22 ASN B 326 LEU B 341 1 16 HELIX 23 23 ASP B 343 LEU B 348 1 6 HELIX 24 24 LEU B 351 GLY B 369 1 19 HELIX 25 25 PRO B 373 GLY B 381 1 9 HELIX 26 26 THR B 383 LYS B 400 1 18 HELIX 27 27 GLN B 407 TYR B 413 1 7 HELIX 28 28 LYS B 414 HIS B 419 5 6 HELIX 29 29 ASP C 0 GLU C 2 5 3 HELIX 30 30 PRO C 45 LYS C 56 1 12 HELIX 31 31 LEU C 87 ALA C 93 1 7 HELIX 32 32 PRO C 100 HIS C 121 1 22 HELIX 33 33 LYS C 129 GLN C 131 5 3 HELIX 34 34 THR C 165 ARG C 169 5 5 HELIX 35 35 ALA C 170 LEU C 175 1 6 HELIX 36 36 THR C 182 ARG C 199 1 18 HELIX 37 37 SER C 207 GLY C 220 1 14 HELIX 38 38 GLY C 229 MET C 233 5 5 HELIX 39 39 ASP C 247 VAL C 252 1 6 HELIX 40 40 ASP C 256 LEU C 267 1 12 HELIX 41 41 SER C 276 ALA C 282 1 7 HELIX 42 42 HIS C 283 GLN C 287 5 5 HELIX 43 43 TYR D 178 CYS D 193 1 16 HELIX 44 44 GLY D 198 GLN D 203 5 6 HELIX 45 45 THR D 207 TYR D 225 1 19 HELIX 46 46 GLN D 228 SER D 244 1 17 HELIX 47 47 LEU D 249 GLY D 251 5 3 HELIX 48 48 LYS D 252 GLU D 269 1 18 HELIX 49 49 GLU D 274 THR D 282 1 9 HELIX 50 50 THR D 287 LEU D 302 1 16 HELIX 51 51 THR D 310 LEU D 320 1 11 HELIX 52 52 ASN D 326 SER D 340 1 15 HELIX 53 53 ASP D 343 LEU D 348 1 6 HELIX 54 54 LEU D 351 THR D 368 1 18 HELIX 55 55 PRO D 373 GLY D 381 1 9 HELIX 56 56 LEU D 387 ALA D 401 1 15 HELIX 57 57 PRO D 402 HIS D 404 5 3 HELIX 58 58 GLN D 407 TYR D 413 1 7 HELIX 59 59 LYS D 414 HIS D 419 5 6 HELIX 60 60 GLY D 420 LEU D 424 5 5 SHEET 1 AA 5 PHE A 4 GLY A 13 0 SHEET 2 AA 5 GLY A 16 ASN A 23 -1 O GLY A 16 N GLY A 13 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLY C 13 0 SHEET 2 CA 5 GLY C 16 ASN C 23 -1 O GLY C 16 N GLY C 13 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 CISPEP 1 ASP B 345 PRO B 346 0 -1.27 CISPEP 2 ASP D 345 PRO D 346 0 6.75 SITE 1 AC1 3 ARG D 410 LYS D 414 HOH D2079 SITE 1 AC2 12 TYR C 15 ALA C 31 LYS C 33 PHE C 80 SITE 2 AC2 12 GLU C 81 LEU C 83 HIS C 84 GLN C 85 SITE 3 AC2 12 ASP C 86 LYS C 89 LEU C 134 ASP C 145 SITE 1 AC3 10 VAL A 18 ALA A 31 LYS A 33 PHE A 80 SITE 2 AC3 10 GLU A 81 LEU A 83 HIS A 84 GLN A 85 SITE 3 AC3 10 LEU A 134 ASP A 145 CRYST1 183.000 183.000 213.560 90.00 90.00 120.00 P 62 2 2 24 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.005464 0.003155 0.000000 0.00000 SCALE2 0.000000 0.006310 0.000000 0.00000 SCALE3 0.000000 0.000000 0.004683 0.00000